

**European LeukemiaNet Consortium
WP 9 - CMPD**

Minute of the Stockholm dinner meeting, 3 June 2005

An informal dinner meeting of the WP9 investigators was organized in Stockholm during the EHA 10 Congress by dr. Gunnar Birgegard.

The following investigators attended the Meeting: Guido Finazzi (Bergamo), Tiziano Barbui (Bergamo), Giovanni Barosi (Pavia) Gunnar Birgegard (Uppsala), Hans Hasselbalch (Denmark), Martin Griesshammer (Ulm), Andreas Reiter (Heidelberg), Jean-Jacques Kiladjian (Paris), Holger Cario (Ulm), John Reilly (Sheffield), Juergen Thiele (Koln), J.J. Michiels (Rotterdam), Pinhas Stark (Israel).

The investigators discussed freely the state-of-the-art of their respective deliverables (see attached list). Major points of discussion and decision taken were:

Deliverable 9.15. The protocol has been prepared by **drs. Hasselbalch and Lengfelder**. However, the launch of the study is pending due to safety issues regarding potential carcinogenicity of Glivec in rat studies raised by the Danish Medicine's Agency. The WP9 chairmen and responsible investigators are in close contact with Novartis Europe (dr. Fincato) and the Danish regulatory Institutions to solve the problem. An answer by the Danish Agency is expected in the next few weeks.

Deliverable 9.16. Dr Reiter communicated that the WP9 website is among the best of the Net! Nevertheless, further improvements can be done and have been discussed. Dr. Reiter and myself will be in contact to reach this goal, taking into account that, at the moment, updating the LeukemiaNet website is not an easy and rapid procedure.

Deliverable 9.18. Dr. Griesshammer communicated that a Registry of pregnancy in MPDs will be on line soon with the technical support of a company. Further details on this project will be provided ASAP.

Deliverables 9.22 and 9.7. Dr. Barosi communicated that a protocol for a phase II clinical study of Velcade in MPD is ready and will be circulated soon. In addition, the proposal for diagnostic, prognostic and staging definitions are also ready.

Deliverable 9.23. A short protocol draft has been prepared with the support of Dr. Marchioli from the Mario Negri Sud Institute who is supposed to be the central coordinator of the study as for the ECLAP project. However, there is a problem of budget since the funds assigned by the LeukemiaNet to this project, as for the others, are quite limited. In the next weeks, Prof. Barbui and myself will have a meeting with Roberto Marchioli to establish if we are in the position to start at least the pilot trial.

Deliverable 9.24. Dr. Birgegard communicated that the study was started and the first patients already registered. The study protocol represents this deliverable.

Deliverable 9.25. Dr. Reiter agreed to deliver some documents regarding this deliverable

Finally, Dr. Kiladjian communicated that an international one-day Meeting devoted to Jak2 mutations in MPDs is going to be organized in Paris next Autumn. This could be the occasion for the next WP9 meeting. I will be in contact with Dr. Kiladjian to finalize this opportunity and all of you will be informed in due time. If this is not possible, the next WP9 meeting will be probably scheduled during the ASH Congress.

Best wishes to all.

Guido Finazzi

Bergamo 8/6/05